Matteo Colina*, Alessia Barisani, Alberto Gualandi, Francesca Poli and Gabriele Campana
Volume6-Issue1
Dates: Received: 2024-12-30 | Accepted: 2025-01-02 | Published: 2025-01-06
Pages: 020-022
Abstract
FullText HTML
FullText PDF
DOI: 10.37871/jbres2052
Certificate of Publication
Copyright
© 2025 Colina M, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Colina M, Barisani A, Gualandi A, Poli F, Campana G. Successful use of Filgotinib in the Treatment of Refractory Rheumatoid Arthritis-Associated Sweet Syndrome. J Biomed Res Environ Sci. 2025 Jan 06; 6(1): 020-022. doi: 10.37871/jbres2052, Article ID: JBRES2052, Available at: https://www.jelsciences.com/articles/ jbres2052.pdf
Subject area(s)
References
- Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet. 2022 Jun;61(6):819-832. doi: 10.1007/s40262-022-01129-y. Epub 2022 May 31. PMID: 35637376; PMCID: PMC9249714.
- Joshi TP, Friske SK, Hsiou DA, Duvic M. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol. 2022 May;23(3):301-318. doi: 10.1007/s40257-022-00673-4. Epub 2022 Feb 14. PMID: 35157247; PMCID: PMC8853033.
- Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. PMID: 31969328.
- Nousari Y, Wu BC, Valenzuela G. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome. Clin Exp Dermatol. 2021 Oct;46(7):1330-1332. doi: 10.1111/ced.14712. Epub 2021 Jun 4. PMID: 33914946.
- Lee YH, Song GG. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol. 2021 May;80(4):379-392. English. doi: 10.1007/s00393-020-00796-1. PMID: 32367211.
